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Chlamydia trachomatis serovar E is one of the most common bacterial sexually transmitted pathogens. Since
it is an obligate intracellular bacterium, efficient colonization of genital mucosal epithelial cells is crucial to the
infectious process. Serovar E elementary bodies (EB) metabolically radiolabeled with 35S-Cys-Met and har-
vested from microcarrier bead cultures, which significantly improves the infectious EB-to-particle ratio,
provided a more accurate picture of the parameters of attachment of EB to human endometrial epithelial cells
(HEC-1B) than did less infectious 14C-EB harvested from flask cultures. Binding of serovar E EB was (i)
equivalent at 35 and 4°C, (ii) decreased by preexposure of EB to heat or the topical microbicide C31G, (iii)
comparable among common eukaryotic cell lines (HeLa, McCoy), and (iv) significantly increased to the apical
surfaces of polarized cells versus nonpolarized cells. In parallel experiments with C. trachomatis serovar L2,
serovar E attachment was not affected by heparin or heparan sulfate whereas these glucosaminoglycans
dramatically reduced serovar L2 attachment. These data were confirmed by competitive inhibition of serovar
E binding and infectivity by excess unlabeled live and UV-inactivated serovar E EB but not by excess serovar
L2 EB. The noninvasive serovar E strains in the lumen of the genital tract enter and exit the apical domains
of target columnar epithelial cells to spread canalicularly in an ascending fashion from the lower to the upper
genital tract. In contrast, the invasive serovar L2 strains are primarily submucosal pathogens and likely use
the glucosaminoglycans concentrated in the extracellular matrix to colonize the basolateral domains of
mucosal epithelia to perpetuate the infectious process.
Chlamydia trachomatis serovars D to K are the leading cause
of bacterially acquired sexually transmitted infections and their
sequelae (18). The infectious process begins by attachment and
entry of chlamydiae in the form of elementary bodies (EB) into
epithelial cells of the genital mucosa. Following endocytosis,
rapid diversion of the EB-containing vesicles to the exocytic
pathway (17), and fusion of individual EB-containing vesicles
with one another, the metabolically inactive EB transform into
metabolically active reticulate bodies (RB), which grow and
divide by binary fission. As the number of progeny increases,
the surrounding membrane expands via added sphingomyelin
from the Golgi complex (6, 7) to keep the developing micro-
colony within a membrane-bound protective niche, termed an
inclusion. Since the RB are noninfectious, conversion of the
RB back into infectious EB in the later stages of this develop-
mental cycle must occur in order for the released EB to infect
neighboring epithelial cells and perpetuate the infectious pro-
cess.
Since chlamydiae are obligate intracellular bacterial patho-
gens and must get inside host cells in order to grow and survive,
adherence of the EB to its target host cell is crucial to a
successful infectious process. Understanding the mechanisms
involved may also offer opportunities for interfering with the
infectious process via microbicides as well as vaccine candi-
dates. Thus, studies of attachment to and entry of chlamydiae
into host cells have been an area of intense investigation for
many years. As new information has emerged, it is clear that
the interactions between the microbe and the host cell are
more complex than perhaps previously appreciated and that
multiple parameters, including culture condition nuances,
which may reflect biological nuances, are important.
One of the leading candidate chlamydial molecules demon-
strated to play an important role in the attachment process is
the major outer membrane protein (MOMP). In an elegant
study by Su et al. (19) using the trachoma-inducing strain C.
trachomatis serovar B and hamster kidney (HaK) cells, it was
shown that MOMP displayed at least two independent but
probably cooperative adhesion functions. Negatively charged
divergent hydrophilic residues exposed in MOMP variable do-
mains II and IV were involved in initial electrostatic interac-
tions to bring the highly negatively charged EB close to the
host cell, after which more specific hydrophobic interactions
took over. Following a conformational change in variable do-
main IV, an invariant nonapeptide sequence—previously lo-
cated in a cryptic, immunoinaccessible cleft—became exposed
and immunoaccessible and promoted binding.
In more recent exciting studies, Zhang and Stephens (31)
reported that Lymphogranuloma venereum (LGV) strain L2,
often designated as C. trachomatis serovar L2, synthesizes a
unique heparan sulfate-like molecule that is required for at-
tachment of chlamydiae to HeLa cells. Exogenous addition of
heparan sulfate or heparin to the culture system effectively
blocked binding of EB to the HeLa cells in a dose-dependent
fashion. In addition, removal of the chlamydial heparan sulfate
adhesin by exposure of EB to heparitinase also blocked attach-
ment; saturation of the enzyme-exposed EB with heparan sul-
fate restored binding of EB to HeLa cells. When identical
experiments were performed on the trachoma-inducing C. tra-
chomatis serovar B, serovar B infectivity was found to be less
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sensitive to the effects of heparan sulfate and heparitinase (2,
3).
In light of the compelling evidence for the role of a heparan
sulfate-like glucosaminoglycan in chlamydial adherence, Su
and colleagues (20) revisited the issue of MOMP as a cytoad-
hesin for HeLa cells with the murine C. trachomatis mouse
pneumonitis (MoPn) strain. To more directly assess the role of
MOMP as an adhesin, in the absence of other chlamydial
envelope components, the mature MOMP polypeptide was
expressed as a fusion protein with the Escherichia coli malE
gene product (MBP-MOMP). Surprisingly, exposure of intact
MoPn EB to heparitinase did not reduce chlamydial infectivity
for HeLa cells. However, exposure of the HeLa cells to hep-
aritinase or exogenous heparan sulfate markedly reduced the
binding of MBP-MOMP to HeLa cells and the infectivity of
whole EB for those treated cells. These findings provided
stronger support for the role of MOMP as an adhesin and,
indeed, pointed to the heparan sulfate proteoglycans as the
host cell receptor to which the MOMP binds. The same strat-
egy has been reported for tropism and infection of Chang
epithelial cells by Neisseria gonorrhoeae MS11—selective bind-
ing of heparan sulfate receptors by gonococcal opacity-associ-
ated protein adhesin(s) (25).
Host cell surface-anchored glucosaminoglycans have also
been shown to be involved in several virus-host cell interac-
tions, including those of human immunodeficiency virus (13),
and bacterium-host interactions, including those of N. gonor-
rhoeae (4, 14, 25). With the added success of the chlamydia-
host cell studies, investigations into the potential use of sul-
fated polysaccharides in vaginal formulations for the purpose
of inhibiting transmission of sexually transmitted disease
agents were prompted (30). Both heparin and heparan sulfate
were, again, capable of blocking infectivity of C. trachomatis
serovar L2 and, in addition, serovar E for nonpolarized ME180
FIG. 1. Comparison of attachment of flask-grown 14C-radiolabeled versus microcarrier-grown 35S-radiolabeled C. trachomatis serovar E EB to HEC-1B cells.
Counts per minute of 14C-labeled EB per 50 ml attached to HEC-1B cells (A) and the percentage of EB attached after 1 h at 35°C (B) were increased as a function
of increasing MOI. Saturation was achieved between 500 and 1,000 EB per host cell. Counts per minute of 35S-labeled EB attached to HEC-1B cells (C) and the
percentage of EB attached after 1 h at 35 and 4°C (D) were increased as a function of increasing MOI. Saturation was apparent at 1,000 EB per host cell. Binding of
EB to HEC-1B cells was slightly better (;10%) at 4°C compared to binding at 35°C.
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FIG. 2. Morphological assessment of binding of flask-grown 14C-labeled C. trachomatis serovar E to McCoy and HEC-1B cells and the infectivity for HEC-1B cells
as a function of MOI. Binding of live, infectious EB to McCoy cells (A, C, and D) and HEC-1B cells (E, G, and H) after 1 h at 35°C was decreased as a function of
decreasing MOI (1,000, 500, and 250). Binding of heat-exposed EB (60°C for 10 min) to McCoy cells (B) and HEC-1B cells (F) at an MOI of 1,000 was considerably
decreased relative to control, unexposed EB (A and E). Infectivity of live EB for HEC-1B cells (I, K, and L), based on the number of inclusions formed at 48 h
postinfection, decreased with decreasing MOI. Preexposure of EB to 60°C in a water bath for 10 min resulted in a loss of infectivity for HEC-1B cells (J). The fluorescent
photomicrographs also confirmed that the eukaryotic cell monolayers were subconfluent, there was no background binding of EB to glass coverslips, and there was no
clumping of EB, especially at the high MOI or following exposure to heat. Magnification, approximately 3300 (A to D and F to L) and approximately 3500 (E).
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cells, although serovar E was considerably less susceptible. To
further analyze the specificity of the heparan sulfate inhibitory
activity, additional sulfated polysaccharides were tested. In es-
sence, the more charged the polyanion, the more it inhibited
chlamydial infectivity for ME180 cells. The investigators con-
cluded that the blocking of chlamydial infectivity by sulfated
polysaccharides, including heparin, was a nonspecific, charge-
mediated event. Further, antigenically distinguishable variants
displayed differing sensitivities to heparan sulfate, as reported
by Chen, Zhang, and Stephens (3).
The chlamydial developmental cycle is slow and asynchro-
nous, at least when performed in vitro in eukaryotic cell lines
grown in plastic tissue culture flasks. For the more rapidly
growing chlamydiae, the Chlamydia psittaci species and the
LGV biovar (C. trachomatis serovars L1, L2, and L3), the
developmental cycle requires ;48 h to complete, and one or
two of every three EB particles is usually infectious. For the
more slowly growing chlamydiae, such as the trachoma-induc-
ing strains (C. trachomatis serovars A to C) and the genital
strains (C. trachomatis serovars D to K), the developmental
cycle requires ;72 to 96 h to complete and the infectious
EB-to-particle ratio is significantly greater. For serovar D, the
infectious EB-to-particle ratio has been estimated to range
from 1:100 to 1:1,678 (11). Incomplete maturation of RB to
infectious EB as well as asynchronous release of infectious
progeny into a rapidly deteriorating environment, consisting of
acidic conditions and lysed host cell debris, may alter outer
membrane components, including adhesins, and compromise
infectivity. Such circumstances might influence the sensitivity
of the trachomatis biovar types (A to K) to heparan sulfate.
Our laboratory has adapted the microcarrier bead culture
method for growing C. trachomatis genital serovar E, and the
results have been dramatic relative to growth of the same
serovar in plastic flasks (21, 29). Two findings are pertinent to
this theme: (i) the developmental cycle is markedly acceler-
ated, and (ii) the isolated EB progeny are as much as 100 to
1,000 times more infectious. The purpose of this study was to
analyze the adherence of the highly infectious microcarrier-
harvested C. trachomatis serovar E EB to host cells (i) by using
various culture condition parameters known or suspected to
influence binding and (ii) by comparing the sensitivity of this
serovar E to heparan sulfate and heparin relative to that of the
C. trachomatis L2 prototype.
MATERIALS AND METHODS
Chlamydiae and host cell lines. C. trachomatis serovar E (UW5-CX) and the
C. trachomatis biovar LGV L2/434/Bu were cultured in McCoy cells grown on
Cytodex 3 microcarrier beads (29) (Pharmacia, Uppsala, Sweden) for approxi-
mately 60 to 65 and 40 h, respectively. The chlamydiae were harvested as crude
stocks and frozen at 270°C in storage buffer (0.02 M phosphate buffer, 0.2 M
sucrose, 5 mM glutamine [2SPG]). An aliquot of frozen stock was rapidly thawed
in a 37°C water bath, and the titer of infectious units was determined, as previ-
ously described (29).
Three eukaryotic cell lines were used for these studies, and all were deter-
mined to be free of mycoplasmas by routine, periodic screening: (i) McCoy cells,
a fibroblast cell line (CRL 1696; American Type Culture Collection [ATCC],
Rockville, Md.); (ii) a transformed human endometrial epithelial cell line, HEC-
subclone 1B (HTB-113; ATCC); and (iii) HeLa 229 (CCL 2.1; ATCC), an
epithelial cell line originating from an adenosquamous carcinoma of the cervix.
Metabolic radiolabeling. McCoy cells, seeded on 75-cm2 flasks for 14C labeling
or Cytodex beads for 35S labeling, were grown in minimal essential medium
FIG. 3. Parameters influencing attachment of microcarrier-grown 35S-radio-
labeled C. trachomatis serovar E EB (MOI, 500:1) to various host cells. (A)
Preexposure of EB to heat (60°C for 10 min) or topical microbicide (C31G)
dramatically reduced attachment of EB to HEC-1B cells after 1 h at 35°C relative
to control, unexposed EB. (B) There was no significant difference in the attach-
ment of EB to nonpolarized HEC-1B cells versus McCoy cells versus HeLa cells
at either 35 or 4°C. (C) However, there was a statistically significant difference
(asterisks signify P , 0.05) in attachment of EB to polarized versus nonpolarized
host cells.
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(MEM) with Hanks’ salts (Gibco, Grand Island, N.Y.) supplemented with 10%
fetal calf serum (FCS) and 2 mM glutamine (MEM-10). When the monolayers
were slightly subconfluent, they were infected with C. trachomatis serovar E and
incubated at 35°C in MEM-10 containing 0.5 mg of cycloheximide per ml. At 16 h
postinfection, the medium was replaced with fresh medium containing 2 mg of
cycloheximide per ml and incubation was continued for an additional 2 h. Prior
to addition of radiolabel, MEM-10 was replaced with MEM-Selectamine (Gibco)
containing a 1/10 volume of each amino acid with a labeled counterpart, 10%
FCS, and 1.5 mg of cycloheximide per ml. For 14C labeling, 0.2 mCi of an
L-14C-amino acid mixture (Dupont NEN, Boston, Mass.) per ml was used. 35S
Easy Tag EXPRESS protein labeling mix (Dupont NEN) was used at a concen-
tration of 10 mCi/ml for cysteine and methionine labeling. Radiolabeled EB were
harvested at 60 to 65 h and purified by a Percoll (Sigma, St. Louis, Mo.) gradient
procedure described by Newhall et al. (10). Infectious unit (IFU) titrations and
protein determinations (bicinchoninic acid; Pierce, Rockford, Ill.) were per-
formed on Percoll-purified radiolabeled EB.
The efficiency of radiolabeling was as follows. For 14C labeling, there were 5 3
1010 EB particles/ml and 1 3 108 IFU/ml; 1 ml of EB 5 1 mg of protein 5 5 3
107 particles 5 1 3 105 IFU, giving 160 dpm. For 35S-Cys-Met labeling, there
were two batches: (i) in the first batch, there were 6 3 109 EB particles/ml and
1.3 3 107 IFU/ml; 1 ml of EB 5 1 mg of protein 5 6 3 106 particles 5 1.3 3 104
IFU, giving 40,000 dpm; (ii) in the second batch, there were 1.65 3 1010 EB
particles/ml and 4 3 108 IFU/ml; 1 ml of EB 5 1 mg of protein 5 1.65 3 107
particles 5 4 3 105 IFU, giving 70,000 to 100,000 dpm. The overall results
obtained from the two preparations were virtually the same.
Attachment assay. HEC-1B, HeLa 229, or McCoy cells were resuspended in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FCS
and 2 mM glutamine, and 0.5 ml of a suspension containing 5 3 104 cells was
added per well (ca. 11.3 mm in diameter) of 48-well plates (Costar). The cultures
were incubated at 37°C for 48 to 72 h until subconfluent monolayers were
obtained, and then they were washed with phosphate-buffered saline (PBS)
containing Ca21 (0.7 mM) and Mg21 (0.5 mM) prior to addition of radiolabeled
EB. Appropriate dilutions of purified, radiolabeled EB (in sucrose-phosphate-
glutamic acid [SPG] storage buffer) were made in 50% SPG–50% DMEM
(devoid of serum), each of which was sonicated for 15 s in a water bath to
disperse any aggregated EB, and 50-ml aliquots were inoculated onto monolayers
in each well. Attachment of EB to host cells was allowed to proceed for 1 h at 35
or 4°C, with gentle tapping of the monolayer every 15 min. For attachment assays
performed at 4°C, the monolayers were prechilled to 4°C prior to the addition of
the EB inoculum.
At the end of the 1-h adsorption period, supernatants were removed, the
monolayers were washed three times in PBS, and the washes were combined with
the supernatants and added to vials containing 4 ml of scintillation fluid (Scin-
tisafe Plus 50%; Fisher Scientific, Fair Lawn, N.J.). Host cell monolayers were
solubilized in 2% sodium dodecyl sulfate, the wells were washed three times in
PBS, and these washes were combined with the host cells for scintillation count-
ing in a Beckman LS 6500 (Beckman, Schaumburg, Ill.). The results are ex-
pressed as (i) counts per minute per 50 ml of radiolabeled EB bound to host cells,
(ii) the number of radiolabeled EB bound per host cell, or (iii) the percentage of
radiolabeled EB attached.
For some analyses, the HEC-1B cells and HeLa cells were grown in a polarized
orientation. In these experiments, Falcon 24-well Biocoat cell culture inserts (ca.
9 mm in diameter; Becton-Dickinson, Bedford, Mass.) were seeded with 104
eukaryotic cells suspended in DMEM-10. The cultures were incubated at 37°C
and monitored until the cells became confluent and reached a polarized state.
The attachment assays were then performed as described for the 48-well cultures.
The raw data were then adjusted for equivalence with the data from the 48-well
cultures for comparison with attachment of EB to nonpolarized cells.
Each experiment was performed in triplicate and was repeated a minimum of
five times on separate days. Data were analyzed by Student’s t test, and a value
of P , 0.05 was considered significant.
Exposure of EB to heparin and heparan sulfate. In accordance with the basic
protocol of Chen, Zhang, and Stephens (3, 31), dilutions of heparin, from
porcine intestinal mucosa (Sigma H-3393), were mixed with 105 IFU of 35S-
labeled serovar E EB, and 50 ml of each suspension was adsorbed to HEC-1B
monolayers for 1 h at 4 or 35°C; the samples were then processed for scintillation
counting. After the initial titration experiments were analyzed, 500 mg of heparin
or heparan sulfate per ml, from bovine intestinal mucosa (Sigma H-7641), was
used in all subsequent attachment assays.
For the fluorescence microscopy experiments, heparan sulfate (500 mg/ml)-
exposed or unexposed, nonradiolabeled, control LGV L2 EB (105 IFU) or C.
trachomatis serovar E EB (105 IFU) were incubated with HEC-1B cells on
coverslips for 1 h at 4 or 35°C for morphological assessment of attachment or
were incubated at 37°C for 36 h (serovar L2) or at 35°C for 48 h (serovar E) for
assessment of infectivity based on inclusion development (16). The monolayer
cultures were then fixed with methanol, stained with a fluorescein-conjugated
pool of monoclonal antibodies generated against the C. trachomatis MOMP,
suspended in an Evans blue counterstain (Syva, Palo Alto, Calif.), and examined
on a Zeiss Axiovert 10 microscope equipped with 495-nm excitation and 520-nm
emission filters.
Competitive inhibition. In order to evaluate the specificity of serovar E at-
tachment, competitive inhibition experiments were performed according to the
method of Su et al. (20). 35S-labeled serovar E EB (105 IFU/ml) were added to
increasing concentrations of nonradiolabeled serovar L2, and the mixtures were
added to HEC-1B cells for 1 h at 4°C and processed for scintillation counting for
analysis of attachment of radiolabeled serovar E EB. For infectivity competition
assays, serovar E EB or serovar L2 EB were irradiated by UV light (at a 70-cm
distance in an open petri dish for 10 min), added in increasing concentrations to
HEC-1B monolayers on coverslips, and incubated for 1 h at 4°C. After three
washes of the monolayers with PBS, live serovar E EB (104 IFU per coverslip)
were inoculated onto the monolayers and the coverslip cultures were incubated
for an additional 1 h at 4°C. Following additional washes, the cultures were
topped up with fresh DMEM and incubated at 37°C for 36 h (serovar L2) or at
35°C for 48 h (serovar E). The infected monolayers were fixed with methanol and
stained with Syva reagent, and the fluorescent chlamydial inclusions in 30 grid
fields at an 340 magnification were counted on each of three coverslips.
RESULTS
Binding parameters of flask-grown 14C-labeled EB. These
studies initially used 14C-metabolically labeled serovar E EB
harvested from infected cells grown in flasks as a baseline for
comparison with previous chlamydial attachment studies (8,
19) and with subsequent attachment studies using microcar-
rier-harvested EB. The basic protocol involved a 1-h adher-
ence time of radiolabeled EB to subconfluent monolayers of
HEC-1B cells in 48-well cluster plates incubated at 35°C in an
atmosphere of 5% CO2.
Increasing the number of EB per cell (multiplicity of infec-
tion [MOI]) resulted in a concomitant increase in attachment
of EB per HEC-1B cell (Fig. 1A). Saturation was achieved
between 500 and 1,000 MOI (Fig. 1B). These quantitative data
were confirmed morphologically with both HEC-1B cells and
McCoy cells although the number of EB attached to McCoy
cells (Fig. 2A, C, and D) appeared slightly less than the num-
ber of EB attached to HEC-1B cells (Fig. 2E, G, and H). The
dose-dependent increase in EB particle attachment was fur-
ther confirmed by a corresponding dose-dependent increase in
HEC-1B cell infectivity as reflected by an increase in the num-
ber of inclusions detected at 48 h (Fig. 2I, K, and L). Preex-
posure of EB to 60°C in a water bath for 5 to 10 min resulted
in a noticeable decrease in attachment of EB to McCoy cells
(Fig. 2B versus A) and HEC-1B cells (Fig. 2F versus E) and a
loss of infectivity of EB for HEC-1B cells (Fig. 2J versus I).
The fluorescent photomicrographs in Fig. 2 provide additional
important information for evaluating the quality of the attach-
ment assays: (i) the eukaryotic cell monolayers were subcon-
fluent; (ii) there was no background binding of EB to the
plastic wells; and (iii) there was no evidence of aggregation of
EB, especially at the high MOI or following exposure of EB to
heat. Ting and colleagues (24) had reported spontaneous ag-
gregation of C. psittaci EB following heat exposure, which
FIG. 4. Fluorescent microscopy analysis of the effect of heparan sulfate on the infectivity of C. trachomatis serovar L2 and serovar E for HEC-1B cells and the
specificity of serovar E infectivity. Numerous serovar L2 inclusions were obtained in HEC-1B cells at 36 h postinfection, whether the initial adherence was performed
at 4°C (A) or 35°C (B). Exogenous addition of heparan sulfate (500 mg/ml) to the serovar L2 EB inoculum during the 4°C adherence (D) or the 35°C adherence (E)
period dramatically reduced subsequent L2 inclusion formation. In contrast, exogenous addition of heparan sulfate to the serovar E inoculum during the 1-h adherence
period had no effect on subsequent serovar E inclusion formation (F) compared to control infections in the absence of heparan sulfate (C). The specificity of the association
of serovar E EB with HEC-1B cells was demonstrated by competitive inhibition of infectivity of live serovar E EB (G) with excess UV-irradiated serovar E EB (H), whereas
excess UV-irradiated serovar L2 EB (I) were not able to competitively inhibit infectivity of serovar E EB. Magnification, 3100 (A to F) and 3400 (G to I).
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interfered with an interpretation of decreased binding and
infectivity.
Binding parameters of microcarrier-grown 35S-labeled EB.
While the fundamental experimental conclusions to this point
were in agreement with those of previous chlamydial attach-
ment studies, we were concerned that the low efficiency of 14C
labeling of EB (essentially 1 dpm per 105 EB) might mask
important aspects of chlamydial adherence. Therefore, we
switched to metabolic radiolabeling of EB with 35S-cysteine-
methionine, which increased the efficiency of serovar E EB
labeling. In addition, all 35S-labeled EB were harvested at 60 h
postinoculation from microcarrier bead-grown cultures, which
increased the infectious titer of these EB progeny.
Again, there was a linear increase in attachment of 35S-EB
to HEC-1B cells with an increase in MOI, and this finding was
true for incubation temperatures of 35 as well as 4°C (Fig. 1C).
There was also a shift in saturation to ;1,000 particles per cell
(Fig. 1D), which agrees with the findings of Ting et al. (24) of
750 particles of C. psittaci GPIC for HeLa cells.
Quantitatively, there was an 80% decrease in binding of
heat-exposed EB to HEC-1B cells (Fig. 3A), which correlates
with the well-recognized heat sensitivity of chlamydiae (26) via
conformational alterations in outer envelope components (19).
For comparison, the radiolabeled EB were preexposed to the
microbicide C31G (0.01%) for 1 h at 4°C prior to the binding
assay. C31G is a mixture of an alkyl dimethyl glycine (alkyl
betaine) and an alkyl dimethyl amine oxide (23). As an am-
photeric surface active agent, its mechanism of action is sus-
pected to involve binding to microbial surfaces via the polar
head group of the amine oxide-betaine and subsequent inter-
calation of the alkyl chains into membranes. The result is a
general destabilization of the outer membrane of gram-nega-
tive bacterial envelopes. Indeed, binding of C31G-exposed EB
to HEC-1B cells was decreased by 75%.
There is sometimes concern that use of different eukaryotic
cell lines may be responsible for variations in data from labo-
ratory to laboratory. However, in these adherence studies, cell
type did not appear to be an issue. There were no significant
differences in the binding of 35S-labeled serovar E EB to
HEC-1B cells versus McCoy cells versus HeLa cells (Fig. 3B).
In fact, the only statistically significant difference found was
that binding of 35S-labeled serovar E EB to polarized host cells
was significantly greater (P , 0.05) than binding to nonpolar-
ized cells (Fig. 3C).
Effect of heparan sulfate and heparin on serovar E EB
attachment and infectivity. The parameters involving micro-
carrier bead-harvested C. trachomatis serovar E adherence to
HEC-1B cells in vitro having been established, the second goal
of these studies was to examine the effects of heparin and
heparan sulfate on serovar E adherence. The prototype studies
by Zhang and Stephens (31) were performed with C. tracho-
matis serovar L2 and HeLa cells at 4°C. Since the first phase of
these studies demonstrated virtually no difference in adher-
ence of serovar E to HEC-1B or HeLa cells and that serovar E
was equally adherent to HEC-1B cells at 4 or 35°C, HEC-1B
cells were used for the heparin-heparan sulfate analyses.
The infectivity of C. trachomatis L2 for HEC-1B cells was
demonstrated by the appearance of numerous inclusions at
36 h postinoculation, whether the initial adherence was per-
formed at 4°C (Fig. 4A) or at 35°C (Fig. 4B). The results were
comparable to the infectivity of serovar E for HEC-1B cells
(Fig. 4C). Addition of heparan sulfate (500 mg/ml) to the
inoculating suspension resulted in a marked decrease in sero-
var L2 infectivity (Fig. 4D and E), similar to that reported
previously (31), and proved that the reagents and protocol
were working in our in vitro system. In contrast, heparan sul-
fate had no obvious effect on serovar E infectivity (Fig. 4F
versus C). To examine these findings with serovar E in a more
quantitative manner, 35S-labeled serovar E EB were adjusted
to an MOI sufficient to yield a 30 to 50% infection of HEC-1B
cells, suspended in heparan sulfate (500 mg/ml), and analyzed
for adherence to HEC-1B cells. Again, in the presence of
heparan sulfate, there was no significant decrease in either the
number of EB attached (Fig. 5A) or the percentage of EB
bound (Fig. 5B) to HEC-1B cells at 4 versus 35°C or to non-
polarized cells versus polarized cells relative to control, radio-
labeled EB not exposed to heparan sulfate.
Even though heparin is more negatively charged than hepa-
ran sulfate, the two glucosaminoglycans appear to behave in a
functionally equivalent manner in reducing the association of
serovar L2 EB with HeLa cells (3). Over a range of concen-
trations of heparin (25 to 500 mg/ml), there was no statistically
significant difference in the number or percentage (Fig. 5C) of
35S-serovar E EB bound to HEC-1B cells at either adherence
temperature. In one experimental series only, suspension of
serovar E EB in 500 mg of heparin per ml resulted in an 18%
decrease in the percentage of (nonpolarized) HEC-1B cell-
bound EB at 35°C (Fig. 5D). By comparison, the presence of
500 mg of heparin per ml was reported to reduce serovar L2
binding by 90% (31) and serovar B infectivity by 56% (2).
To determine if a longer exposure of EB to heparin or,
alternatively, different buffers were necessary to effect reduced
association of serovar E with HEC-1B cells, 35S-serovar E EB
were diluted in our standard buffer (SPG-DMEM) or PBS and
preexposed to heparin for 1 h at 4°C prior to the 1-h adherence
time. Extended preexposure of EB to heparin (Fig. 5E) versus
immediate exposure (Fig. 5F) did not alter the binding of
serovar E EB to HEC-1B cells when SPG-DMEM was the
suspension buffer. Preincubation of heparin-EB in PBS re-
sulted in a ;10% reduction in binding.
The specificity of the association of serovar E EB with
HEC-1B cells was demonstrated by competitive inhibition of
infectivity of live serovar E EB with excess UV-irradiated (20)
serovar E EB (Fig. 4G and H and 6A) whereas excess UV-
irradiated serovar L2 EB were not able to competitively inhibit
infectivity of serovar E EB (Fig. 4I and 6B). Further, excess
viable serovar L2 EB were unable to competitively inhibit
binding of 35S-labeled serovar E EB to HEC-1B cells (Fig. 6C).
DISCUSSION
Relative to previous studies (8), three important differences
in binding of C. trachomatis serovar E EB to host cells were
noted in this study. First, binding did occur at 4°C. Second, the
use of more infectious EB harvested from microcarrier beads
did provide for a greater number of EB bound rapidly per host
FIG. 5. Quantitative effect of heparan sulfate or heparin on the association of 35S-radiolabeled C. trachomatis serovar E EB with HEC-1B cells. Exogenous addition
of heparan sulfate (500 mg/ml) made no difference in the number of labeled EB bound to nonpolarized or polarized HEC-1B cells after 1 h at 35 or 4°C (A) or the
percentage of 35S-EB bound (B). Similarly, exogenous addition of increasing concentrations of heparin did not significantly alter the percentage of radiolabeled EB
bound to HEC-1B cells at 35 or 4°C (C) or to HEC-1B or HeLa cells at 4°C (D). Alternatively, EB were diluted either in our standard SPG-DMEM buffer or in PBS
and were then preexposed to heparin for 1 h at 4°C prior to the 1-h adherence assay (E) or subjected to immediate exposure to heparin during the adherence assay
(F). None of these manipulations affected the percentage of EB binding to HEC-1B cells more than 10%.
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cell, which could be better documented by using more effi-
ciently radiolabeled 35S-EB. Previous attempts to increase the
efficiency of labeling of EB by using 125I were unsuccessful due
to a marked loss of EB infectivity (5). Third, attachment of EB
to the apical surfaces of polarized epithelial cells was signifi-
cantly greater than attachment of EB to nonpolarized cell
surfaces.
The number of serovar E EB bound to HEC-1B cells at 4°C
was always equal to or even slightly better, by ;10%, than that
of EB bound at 35°C. While it would be understandable that
the number of organisms bound at 4°C could be slightly greater
than the number bound at 35°C due to an increase in the
number of receptors available, from lack of receptor recycling,
the same phenomenon should be true for HeLa and McCoy
cells. One of the difficulties in obtaining an accurate measure-
ment of EB binding at 4°C is that eukaryotic cells tend to
round up from cold shock and detach from plastic surfaces. In
our hands, HEC-1B cells seemed to be somewhat less suscep-
tible to the 4°C temperature shift than were HeLa or McCoy
cells, especially when we used the SPG-DMEM diluent con-
taining 10 mM HEPES buffer; the sucrose provides some cryo-
protection, and the buffer maintains the pH of the cultures
near neutral. Alternative strategies employed to circumvent
the difficulties of a 4°C temperature shift for binding analyses
have included prefixation of host cells with glutaraldehyde or
sodium azide and then performance of binding analyses at
35°C. HEC-1B cells were more susceptible to these prefixation
maneuvers, and significant numbers of cells were lost from the
monolayers during the numerous washing steps. We and others
(24) have seen a 40% reduction in EB binding to glutaralde-
hyde-fixed cells. Even though some of the reduction may be
explained by glutaraldehyde-mediated receptor cross-linking,
we were concerned about the accuracy of such analyses.
Another explanation for the slight discrepancies in binding
of C. trachomatis EB at 4°C to HeLa and McCoy cells is that
comparisons have been made relative to binding analyses at
37°C. The reason that we use the 35°C incubation temperature
is that Lee (9) reported a 10 to 30% decrease in serovar A
inclusion development with an incubation temperature of 37
versus 35°C. In extensive studies of the kinetics of neutraliza-
tion of chlamydiae, Peeling and Brunham (11) also docu-
mented that the sensitivity of trachoma serovars to heat is
greater than that of the LGV serovars. Without an added
component for thermal protection in PBS buffer, serovar D
infectivity dropped 30 to 50% in 30 min at 37°C. While these
culture condition nuances may often explain discrepancies in
results from laboratory to laboratory, the emphasis should be
on what such nuances tell us about the biology of chlamydiae.
As to the heparin-heparan sulfate experiments, exogenous
addition of the glucosaminoglycans did not affect association
or infectivity of serovar E EB with host eukaryotic cells at
either 4 or 35°C, while in side-by-side experiments with LGV
serovar L2, both binding and infectivity were dramatically af-
fected, as reported by Zhang and Stephens (31). The specificity
of the attachment was confirmed by competitive inhibition
studies.
How might our understanding of the biological differences
between the two serovars help us explain the quite different
results obtained in our binding analyses involving heparin and
FIG. 6. Competitive inhibition of infectivity and binding of serovar E EB to
HEC-1B cells. Infectivity of serovar E EB for HEC-1B cells was competitively
inhibited by increasing concentrations of unlabeled, UV-irradiated serovar E EB
(A) but not by increasing concentrations of UV-irradiated serovar L2 EB (B).
Binding of 35S-serovar E EB to HEC-1B cells at 4°C was not competitively
inhibited by increasing concentrations of live serovar L2 EB (C).
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heparan sulfate? The C. trachomatis species is subdivided into
(i) the C. trachomatis MoPn biovar, (ii) the C. trachomatis
biovar, and (iii) the LGV biovar. The latter two biovars are
strictly human pathogens and exhibit nearly 100% homology at
the DNA level. The human C. trachomatis biovars can be
further subdivided into serological variants or serovars: A, B,
Ba, and C are responsible for the blinding eye disease tra-
choma, and D to K are responsible for sexually transmitted
diseases. The three serovars (L1, L2, and L3) of the LGV
biovar are also responsible for causing sexually transmitted
diseases, but the sexually transmitted diseases caused by the
two human biovars are markedly different. C. trachomatis se-
rovars D to K are luminal pathogens. Following initial infec-
tion of the epithelial cells lining the endocervical canal, the
chlamydiae may spread canalicularly to the fundus of the
uterus to cause endometritis and ascend into the fallopian
tubes to cause salpingitis (18). In contrast, the more invasive
LGV biovar preferentially infects cells of the lymph nodes. The
first manifestation of the disease is a painless, superficial ulcer
or vesicle on the genitals. Within 1 to 3 weeks after appearance
of the primary lesion, regional lymphadenopathy develops.
While the course of the disease is variable, in cases of persis-
tent infection, progressive destruction of the genitalia and gen-
itourinary tract may occur. Due to perirectal drainage of lymph
nodes from the vagina, women may experience proctitis and
perirectal abscesses. LGV organisms also spread systemically
via the bloodstream and can enter the central nervous system
(12).
At the in vitro level, several differences between serovar E
and serovar L2 have been documented experimentally, besides
the more rapid maturation of serovar L2 inclusions at 48 h
versus the later maturation of serovar E inclusions at 60 to
72 h. Previous studies using inhibitors of the cytoskeletal net-
work demonstrated that disruption of microfilaments with cy-
tochalasin D markedly reduced entry, early vesicle fusion, and
inclusion development of serovar E in HEC-1B cells but not
that of serovar L2. Conversely, disruption of microtubules with
colchicine or nocodazole had no effect on serovar E inclusion
development but resulted in altered serovar L2 early and
midinclusion development (16). These results implied that C.
trachomatis serovar E may utilize a different pathway for up-
take and infection from that of LGV serovar L2, a finding
which has been suggested in these studies. Chlamydial devel-
opment in the trans-Golgi network occurs in the supranuclear
apical region of polarized mucosal epithelia. Either the aber-
rant exocytic inclusion (7, 22) containing serovar E then fuses
with the apical membrane of the infected cell to release EB
progeny into the lumen, or the EB “sneak out” the apical
domain gradually (29). In contrast, the L2-containing inclusion
or released progeny may exploit the apical-to-basolateral axis
of microtubule bundles to position themselves for basal exit
into the submucosa (16). Further, in accordance with the di-
rectional infectious process in vivo, we have demonstrated that,
in polarized epithelial cells in vitro, serovar L2 progeny do exit
through the basal domain, as if en route to the lymph nodes
(27).
The isoform of heparan sulfate associated with simple epi-
thelia in vivo is localized to basolateral surfaces (1, 28). Thus,
it makes sense topologically for the more invasive chlamydial
strains, such as LGV, to exploit heparan sulfate, perhaps as an
adhesin, and for the heparan sulfate receptors to concentrate
at mucosal epithelia for reentry at the basolateral domains
from their submucosal location to perpetuate the infectious
process. This rationale, if true, could also explain the absence
of a heparan sulfate effect on luminal serovar E EB.
Chlamydiae do not possess flagella or appendages such as
pili or fimbriae. Thus, the mechanisms used by chlamydiae to
facilitate colonization of target mucosal epithelial cells have
remained unknown. A plausible explanation could be that in-
vasive chlamydiae exploit numerous low-affinity heparan sul-
fate receptors to reduce the dimensionality of their diffusion in
the extracellular matrix from three to two dimensions (15),
thereby increasing their local concentration at the basolateral
membrane; this sets up the probability for other domains of the
chlamydial adhesin GAG acceptor ligand (3), MOMP (19, 20),
the 60-kDa OMP (24), or some other chlamydial ligand then
interacting with high-affinity receptors for effecting entry.
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